- Home
- NAUT vs SABA Comparison
NAUT vs SABA Comparison
Compare NAUT & SABA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
HOLD
Current Price
$2.20
Company Overview
Basic Information| Metric | NAUT | SABA |
|---|---|---|
| Founded | 2016 | 1988 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Laboratory Analytical Instruments | |
| Sector | Industrials | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 269.0M | 240.1M |
| IPO Year | N/A | N/A |
Fundamental Metrics
Financial Performance| Metric | NAUT | SABA |
|---|---|---|
| Price | $2.20 | $8.03 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 178.5K | ★ 290.0K |
| Earning Date | 02-26-2026 | 01-01-0001 |
| Dividend Yield | N/A | ★ 12.91% |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.62 | $3.64 |
| 52 Week High | $2.54 | $4.42 |
Technical Indicators
Market Signals| Indicator | NAUT | SABA |
|---|---|---|
| Relative Strength Index (RSI) | 54.82 | 27.21 |
| Support Level | $1.97 | $8.01 |
| Resistance Level | $2.20 | $8.12 |
| Average True Range (ATR) | 0.17 | 0.09 |
| MACD | 0.01 | 0.00 |
| Stochastic Oscillator | 73.29 | 12.50 |
Price Performance
Historical Comparison NAUT
SABA
About NAUT Nautilus Biotechnolgy Inc.
Nautilus Biotechnology Inc is a development stage life sciences company creating a platform technology for quantifying and unlocking the complexity of the human proteome. The Company transform the field of proteomics by democratizing access to the proteome and enabling fundamental advancements across human health and medicine. Company's products includes: Proteome Analysis System, Reagent Kits, Software and analysis.
About SABA Saba Capital Income & Opportunities Fund II Shares of Beneficial Interest
Saba Capital Income & Opportunities Fund II is a closed-end fund. The company seeks high current income, with a secondary goal of capital appreciation. The fund invests in fixed income markets across the globe.